id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-0874-0052,FDA,FDA-2021-N-0874,Intarcia Letter to Office of the Commissioner,Other,Letter(s),2021-12-29T05:00:00Z,2021,12,2021-12-29T05:00:00Z,,2021-12-29T13:57:57Z,,0,0,0900006484f0006f
FDA-2021-N-0874-0002,FDA,FDA-2021-N-0874,Request for Hearing from Hogan Lovells US LLP (Intarcia Therapeutics Inc.),Other,Request for Hearing,2021-09-13T04:00:00Z,2021,9,2021-09-13T04:00:00Z,,2021-09-13T20:06:58Z,,0,0,0900006484d795f2
FDA-2021-N-0874-0001,FDA,FDA-2021-N-0874,Proposal To Refuse To Approve a New Drug Application for ITCA 650 (Exenatide in DUROS Device); Opportunity for a Hearing,Notice,General Notice,2021-09-02T04:00:00Z,2021,9,2021-09-02T04:00:00Z,2021-11-02T03:59:59Z,2024-11-12T23:33:26Z,2021-18928,1,0,0900006484d4387c